Alternatives to insulin lispro
FDA shortage status is active for insulin lispro; 2 same-class SPL records are listed below for registry comparison only.
Brand: Humalog
insulin lispro class peers while FDA lists an active shortage
insulin lispro (Humalog) is on an FDA shortage listing while 2 other Rapid-Acting Insulin SPL records remain in this registry peer set (class inventory 3). Labeled indication field for insulin lispro: Admelog is used to improve blood sugar control in people with diabetes.
Top FAERS reaction fields for insulin lispro total 84,866 reports across 10 reactions, set beside insulin aspart, insulin glulisine. Counts are exposure-weighted submissions, not per-patient risk.
About insulin lispro
Admelog is a rapid-acting insulin that helps control blood sugar levels. It is used to treat diabetes in adults and children.
Used for: Admelog is used to improve blood sugar control in people with diabetes. Diabetes is a disease where your body does not make enough insulin or cannot use insulin properly. This medicine helps your body use sugar from the food you eat.
2 Rapid-Acting Insulin peers (wide set)
insulin aspart
RxNovoLog, Fiasp
NovoLog is used to improve blood sugar control in adults and children with diabetes. Diabetes is a condition where your body doesn't make enough insulin or can't use insulin properly, leading to high blood sugar. This medicine helps to lower your blood sugar levels.
insulin glulisine
RxApidra
Apidra is used to improve blood sugar control in adults and children with diabetes. Diabetes is a condition where your body does not make enough insulin or cannot use insulin properly, leading to high blood sugar levels. This medicine helps to lower your blood sugar levels.
insulin lispro vs insulin aspart & insulin glulisine · FAERS reaction fields
FAERS top-reaction field "Blood Glucose Increased" shows the widest count spread between insulin lispro and insulin aspart, insulin glulisine in this extract (27,756-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | insulin lispro | insulin aspart | insulin glulisine |
|---|---|---|---|
| Blood Glucose Increased | 38,180 | 10,424 | 1,526 |
| Incorrect Dose Administered | 9,067 | - | - |
| Blood Glucose Decreased | 8,761 | 3,344 | 445 |
| Visual Impairment | 5,392 | - | - |
| Nausea | 4,787 | 3,724 | 370 |
| Malaise | 3,946 | 1,789 | 392 |
| Hypoglycaemia | 3,800 | - | 756 |
| Fatigue | 3,754 | 2,664 | 297 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
insulin lispro shortage vs Rapid-Acting Insulin peer index
Shortage status
FDA shortage listing is active for insulin lispro (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for insulin lispro while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for insulin lispro: see also the generic vs brand label guide when reading Humalog SPL strings.
Read our methodology - how this data is sourced, computed, and verified.